학술논문

Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation.
Document Type
Article
Source
Neuropathology & Applied Neurobiology. Apr2008, Vol. 34 Issue 2, p216-230. 15p. 3 Charts, 6 Graphs.
Subject
*ALLERGIC encephalomyelitis
*AUTOIMMUNE diseases
*NEUROBIOLOGY
*NEUROLOGICAL disorders
*CHRONIC diseases
Language
ISSN
0305-1846
Abstract
During neuroinflammation in multiple sclerosis (MS) fibrinogen, not normally present in the brain or spinal cord, enters the central nervous system through a compromised blood–brain barrier. Fibrin deposited on axons is ineffectively removed by tissue plasminogen activator (tPA), a key contributory factor being the upregulation of plasminogen activator inhibitor-1 (PAI-1). Aims: This study investigated the role of PAI-1 during experimental neuroinflammatory disease. Methods: Chronic relapsing experimental allergic encephalomyelitis (CREAE), a model of MS, was induced with spinal cord homogenate in PAI-1 knockout (PAI-1−/−) and wild type (WT) mice, backcrossed onto the Biozzi background. Results: Disease incidence and clinical severity were reduced in PAI-1−/− mice, with animals developing clinical signs significantly later than WTs. Clinical relapses were absent in PAI-1−/− mice and the subsequent reduction in neuroinflammation was coupled with a higher capacity for fibrinolysis in spinal cord samples from PAI-1−/− mice, in association with increased tPA activity. Axonal damage was less apparent in PAI-1−/− mice than in WTs, implicating fibrin in both inflammatory and degenerative events during CREAE. Conclusions: PAI-1 is a potential target for therapy in neuroinflammatory degenerative diseases, allowing effective fibrin removal and potentially reducing relapse rate and axonal damage. [ABSTRACT FROM AUTHOR]